The virus SARS-Cov-2 has created a pandemic originating in China in the year 2019 and has spread over the whole world. This pandemic has cost many lives and a large number of people has not yet recovered from the symptoms of the disease. It has also challenged modern day global economic interactions and has severely disrupted international supply chains and has internationally created a huge number of unemployed people. The most promising remedy for this pandemic is the generation of a vaccine that targets this viral infection, does not produce ADE (antibody dependent enhancements), and creates antibodies that exist in the body for extended periods of time.
We have developed a strategy to achieve these goals and we filed in August 2020 for a patent that covers the methodology to design such vaccine.